Olanzapine versus placebo in the treatment of acute mania

American Journal of Psychiatry

Volumn 156, Issue 5, 1999, Pages 702-709

  Tohen, Mauricio ^a   Sanger, Todd M ^b   McElroy, Susan L ^b   Tollefson, Gary D ^b   Chengappa, K N Roy ^b   Daniel, David G ^b   Petty, Frederick ^b   Centorrino, Franca ^b   Wang, Richard ^b   Grundy, Starr L ^b   Greaney, Michael G ^b   Jacobs, Thomas G ^b   David, Stacy R ^b   Toma, Verna ^b  

^a ELI LILLY AND COMPANY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

OLANZAPINE;

ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MANIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SOMNOLENCE; VERTIGO; WEIGHT GAIN; XEROSTOMIA;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEADACHE; HUMANS; MALE; MIDDLE AGED; PATIENT DROPOUTS; PIRENZEPINE; PLACEBOS; PSYCHIATRIC STATUS RATING SCALES; SLEEP; TREATMENT OUTCOME;

EID: 0032919745     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Regier DA, Myers JK, Kramer M, Robins LN, Blazer DG, Hough RL, Eaton WW, Locke BZ: The NIMH Epidemiologic Catchment Area Program: historical context, major objectives, and study population characteristics. Arch Gen Psychiatry 1984; 41:934-941
2. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen H-U, Kendler KS: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51:8-19
3. Tohen M, Goodwin FK: Epidemiology of bipolar disorder, in Psychiatric Epidemiology. Edited by Tsuang MT, Tohen M, Zahner G. New York, John Wiley & Sons, 1995, pp 301-316
4. American Psychiatric Association: Practice Guideline for the Treatment of Patients With Bipolar Disorder. Am J Psychiatry 1994; 151(Dec suppl)
5. Kane JM: The role of neuroleptics in manic-depressive illness. J Clin Psychiatry 1988; 49(Nov suppl):12-14
6. Goodwin FK, Jamison KR: Manic-Depressive Illness. New York, Oxford University Press, 1990
7. Post RM, Uhde TW, Roy-Byrne PP, Joffe RT: Correlates of antimanic response to carbamazepine. Psychiatry Res 1987; 21:71-83
8. Tohen M, Zhang F, Zarate C Jr, Taylor C, Sanger T, Burns P, Tollefson GD: Neuroleptic use in bipolar disorder: a pharmacoepidemiologic review, in 1998 Annual Meeting New Research Program and Abstracts. Washington, DC, American Psychiatric Association, 1998, pp 221-222
9. Bowden CL: Dosing strategies and time course of response to antimanic drugs. J Clin Psychiatry 1996; 57(suppl 13):4-9
10. Bowden CL: Treatment of bipolar disorder, in The American Psychiatric Press Textbook of Psychopharmacology. Edited by Schatzberg AF, Nemeroff CB. Washington, DC, American Psychiatric Press, 1995, pp 603-614
11. Zarate CA Jr, Tohen M, Baldessarini RJ: Clozapine in severe mood disorders. J Clin Psychiatry 1995; 56:411-417
12. Calabrese JR, Kimmel SE, Woyshville MJ, Rapport DJ, Faust CJ, Thompson PA, Meltzer HY: Clozapine for treatment-refractory mania. Am J Psychiatry 1996; 153:759-764
13. Frye MA, Ketter TA, Altshuler LL, Denicoff K, Dunn RT, Kimbrell TA, Cora-Locatelli G, Post RM: Clozapine in bipolar disorder: treatment implications for other atypical antipsychotics. J Affect Disord 1998; 48:91-104
14. Suppes T, Rush AJ, Webb A, Carmody T, Kraemer H: A one-year randomized trial of clozapine vs usual care in bipolar I patients (abstract). Biol Psychiatry 1996; 39:531
15. Zarate CA Jr, Tohen M, Banov MD, Weiss MK, Cole JO: Is clozapine a mood stabilizer? J Clin Psychiatry 1995; 56:108-112
16. Baldessarini RJ, Frankenburg FR: Clozapine: a novel antipsychotic agent. N Engl J Med 1991; 324:746-754
17. Tohen M, Zarate CAJ, Centorrino F, Hegarty JI, Froeschl M, Zarate SB: Risperidone in the treatment of mania. J Clin Psychiatry 1996; 57:249-253
18. Keck PEJ, Wilson DR, Strakowski SM, McElroy SL, Kizer DL, Balistreri TM, Holtman HM, DePriest M: Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders. J Clin Psychiatry 1995; 56:466-470
19. Moore NA, Calligaro DC, Wong DT, Bymaster FP, Tye NC: The pharmacology of olanzapine and other new antipsychotic agents. Current Opinions in Investigational Drugs 1993; 2: 281-293
20. Tollefson GD, Sanger TM, Lu MK, Thieme ME: Depressive signs and symptoms in schizophrenia-a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 1998;55:250-258
21. Beasley CM Jr, Hamilton S, Crawford AM, Dellva M, Tollefson GD, Tran PV, Beuzen J, Olanzapine E003 Study Group: Olanzapine versus haloperidol: acute-phase results of the International double-blind olanzapine trial. Eur Neuropsychopharmacol 1997; 7:125-137
22. Beasley CM Jr, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S: Olanzapine versus placebo: results of a doubleblind, fixed-dose olanzapine trial. Psychopharmacology (Berl) 1996; 124:159-167
23. Hamilton SH, Revicki DA, Genduso LA, Beasley CM Jr: Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial. Neuropsychopharmacology 1997; 18:41-49
24. Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME: Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997; 154:457-465
25. Beasley CM Jr, Tollefson G, Tran PV, Satterlee W, Sanger T, Hamilton S, Olanzapine HGAD Study Group: Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996; 14:111-123
26. Zarate CJ, Narendran R, Tohen M, Greaney J, Berman A, Pike S, Madrid A: Clinical predictors of acute response with olanzapine in psychotic mood disorders. J Clin Psychiatry 1998; 59:24-28
27. McElroy SL, Frye MA, Denikoff KD, Altshuler LL, Nolen W, Kupka R, Suppes T, Keck PE, Leverich GS, Kmetz GF, Post PM: Olanzapine in treatment-resistant bipolar disorder. J Affect Disord 1998; 49:119-122
28. Ravindran AV, Jones BW, Al-Zaid K, Lapierre YD: Effective treatment of mania with olanzapine: 2 case reports. J Psychi-atry Neurosci 1997; 22:345-346
29. Tohen M, Sanger T, Tollefson GD, McElroy SL: Olanzapine versus haloperidol in the treatment of schizoaffective bipolar patients, in 1997 Annual Meeting New Research Program and Abstracts. Washington, DC, American Psychiatric Association, 1997, pp 123-124
30. Spitzer RL, Williams JBW, Gibbon M, First MB: The Structured Clinical Interview for DSM-III-R (SCID), I: history, rationale, and description. Arch Gen Psychiatry 1992; 49:624-629
31. Young RC, Biggs JT, Ziegler VE, Meyer DA: A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133:429-435
32. Hamilton M: Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6:278-296
33. Kay S, Opler L, Fiszbein A: Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY, Multi-Health Systems, 1986
34. Spearing MK, Post PM, Leverich GS, Brandt D, Nolen W: Modification of the Clinical Global Impression (CGI) scale for use in bipolar illness (BP): the CGI-BP. Psychiatr Res 1997; 73:159-171
35. Ware JE, Snow KK, Kosinski M, Gandek B: SF-36 Health Survey Manual and Interpretation Guide. Boston, Health Institute, New England Medical Center, 1993
36. Ware JE, Kosinski M, Keller SD: Physical and Mental Health Summary Scales: A User's Manual. Boston, Health Institute, New England Medical Center, 1994
37. Simpson GM, Angus JWS: A rating scale for extrapyramidal side effects. Act Psychiatr Scand Suppl 1970; 212:11-19
38. Barnes TR: A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154:672-676
39. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication Adm 76-338. Washington, DC, US Department of Health, Education, and Welfare, 1976, pp 534-537
40. SAS/STAT User's Guide, version 6, 4th ed. Cary, NC, SAS Institute, 1990
41. Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F, Dilsaver SC, David JM, Rush AJ, Small JG, Garza-Trevino ES, Risch C, Goodnick PJ, Morris DD: Efficacy of divalproex versus lithium and placebo in the treatment of mania. JAMA 1994; 271:918-924
42. Pope HGJ, McElroy SL, Keck PE, Hudson JI: Valproate in the treatment of acute mania: a placebo-controlled study. Arch Gen Psychiatry 1991; 48:62-68
43. Spitzer RL, Endicott J, Robins E: Research Diagnostic Criteria (RDC) for a Selected Group of Functional Disorders, 2nd ed. New York, New York State Psychiatric Institute, Biometrics Research, 1975
44. Kukopulos A, Reginaldi D, Laddomada P, Floris G, Serra G, Tondo L: Course of the manic depressive cycle and changes caused by treatment. Pharmacopsychiatria 1980; 13:156-167
45. White E, Cheung P, Silverstone T: Depot antipsychotics in bipolar affective disorder. Int Clin Psychopharmacol 1993; 8: 119-122
46. Gelenberg AJ, Hopkins HS: Antipsychotics in bipolar disorder. J Clin Psychiatry 1996; 57(suppl 9):49-52
47. Ahlfors UG, Baastrup PC, Dencker SJ, Elgen K, Lingjaerde O, Pedersen V, Schou M, Aaskoven O: Flupenthixol decanoate in recurrent manic-depressive illness. Acta Psychiatr Scand 1981: 64:226-237
48. Morgan HG: The incidence of depressive symptoms during recovery from hypomania. Br J Psychiatry 1972; 120:537-539
49. Tohen M, Zarate CJ: Antipsychotic agents and bipolar disorder. J Clin Psychiatry 1998; 59(suppl 1):38-48
50. McElroy SL, Keck PEJ, Strakowski SM: Mania, psychosis, and antipsychotics. J Clin Psychiatry 1996; 57(suppl 3):14-26
51. Kane JM, Woerner M, Weinhold P, Wegner J, Kinon B: A prospective study of tardive dyskinesia development: preliminary results. J Clin Psychopharmacol 1982; 2:345-349
52. Tran PV, Dellva MA, Tollefson GD, Beasley CM Jr, Potvin JH, Kiesler GM: Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry 1997; 58:205-211
53. Tollefson GD, Beasley CM Jr, Tamura RN, Tran PV, Potvin JH: A blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 1997; 154:1248-1254
54. Janicak PG, Sharma RP, Easton M, Cornat JE, Davis JM: A double-blind, placebo-controlled trial of clonidine in the treatment of acute mania. Psychopharmacol Bull 1989; 25:243-245
55. Lenox RH, Newhouse PA, Creelman WL, Whitaker TM: Adjunctive treatment of manic agitation with lorazepam versus haloperidol: a double-blind study. J Clin Psychiatry 1992; 53: 47-52